Abstract Details

Title Seizure Severity and Cognition: A Longitudinal Study Investigating Epilepsy Patients and Status Epilepticus Survivors

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) S36 - Epilepsy Basic Mechanisms, Status Epilepticus, and Mortality (2:48 PM-3:00 PM)

Poster/Presentation
Number 010

Background Cognitive impairments have been described as an essential comorbidity of epilepsy. Despite the importance of routine cognitive testing in PwE or the potential use of cognitive tests for triaging patients to resource-intensive neuropsychological evaluations, the validity of cognitive tests for PwE remains understudied. Impaired cognition after SE is commonly reported but is even less understood. Cognitive prognosis for SE survivors is also limited by inconsistent or minimal investigation into clinical factors that are associated with impaired cognition.

Objective To evaluate the feasibility of a computerized cognitive testing battery called Creyos in people with epilepsy (PwE) for comparison to status epilepticus (SE) survivors longitudinally.

Design/Methods Adult PwE were recruited from the Epilepsy Monitoring Unit and SE survivors were recruited from two Intensive Care Units in London, Ontario, Canada. Using an iPad, participants completed the Creyos battery which involves 12 tasks evaluating various cognitive abilities. PwE completed the battery once and SE survivors complete the battery five times over one year (SE data collection is ongoing). Participants’ scores were compared to age- and sex-matched norms from the Creyos database.

Results PwE (N = 45) performed worse than matched norms on 11 tasks (p < .01) and in the three domains that the 12 tasks map onto: short-term memory (t = -5.19), reasoning (t = -3.17), and verbal processing (t = -7.53). There were no relationships between PwE’s Creyos performance and clinical factors (for example, epilepsy duration, generalized versus temporal lobe epilepsy). The most up-to-date data, including longitudinal results from SE survivors, will be presented.

Conclusions Creyos is feasible for PwE and illustrated the widespread cognitive impairment among PwE. This data will be compared to SE survivors’ Creyos performance longitudinally during the recovery trajectory to evaluate cognitive recovery from SE and the relationship between seizure severity and cognition.

Authors/Disclosures
Hannah G. Gray, MSc PRESENTER	Ms. Gray has received personal compensation in the range of $500-$4,999 for serving as a AAN 2025 Annual Meeting Abstract Co-Author and Presenter with Creyos.
Karnig Kazazian, PhD	Mr. Kazazian has nothing to disclose.
Conor J. Wild, PhD	Dr. Wild has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Creyos.
Derek Debicki, MD	Dr. Debicki has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Canada Inc.. The institution of Dr. Debicki has received research support from Academic Medical Association of Southwestern Ontario. The institution of Dr. Debicki has received research support from Western BrainScan. The institution of Dr. Debicki has received research support from Lawson Research. The institution of Dr. Debicki has received research support from Canadian Institutes of Health Research.
Adrian Owen (The Brain and Mind Institute)	Adrian Owen has stock in Creyos Inc.
Teneille Gofton, MD (London Health Sciences Centre)	The institution of Dr. Gofton has received research support from Government of Canada. The institution of Dr. Gofton has received research support from Canadian Institutes of Health Research. The institution of Dr. Gofton has received research support from Academic Medical Organisation of Southwestern Ontario. The institution of Dr. Gofton has received research support from Lawson Health Research Institute. Dr. Gofton has a non-compensated relationship as a Medical Advisory Board Member with NORSE Institute that is relevant to AAN interests or activities.

��ɫ��

��ɫ��